Literature DB >> 25463699

Nonopioid substance use disorders and opioid dose predict therapeutic opioid addiction.

Kelly L Huffman1, Elizabeth R Shella2, Giries Sweis3, Sandra D Griffith4, Judith Scheman3, Edward C Covington2.   

Abstract

UNLABELLED: Limited research examines the risk of therapeutic opioid addiction (TOA) in patients with chronic noncancer pain. This study examined TOA among 199 patients undergoing long-term opioid therapy at the time of admission to a pain rehabilitation program. It was hypothesized that nonopioid substance use disorders and opioid dosage would predict TOA. Daily mean opioid dose was 132.85 mg ± 175.39. Patients with nonopioid substance use disorders had 28 times the odds (odds ratio [OR] = 28.58; 95% confidence interval [CI] = 10.86, 75.27) of having TOA. Each 50-mg increase in opioid dose nearly doubled the odds of TOA (OR = 1.73; 95% CI = 1.29, 2.32). A 100-mg increase was associated with a 3-fold increase in odds (OR = 3.00; 95% CI = 1.67, 5.41). Receiver operating characteristic analysis revealed that opioid dose was a moderately accurate predictor (area under the curve = .75; 95% CI = .68, .82) of TOA. The sensitivity (.70) and specificity (.68) of opioid dose in predicting TOA was maximized at 76.10 mg; in addition, 46.00 mg yielded 80% sensitivity in identifying TOA. These results underscore the importance of obtaining a substance use history prior to prescribing and suggest a low screening threshold for TOA in patients who use opioids in the absence of improvement in pain or functional impairment. PERSPECTIVE: This article examines TOA in patients with chronic noncancer pain undergoing long-term opioid therapy. Results suggest that patients should be screened for nonopioid substance use disorders prior to prescribing. In the absence of improvement in pain or function, there is a low threshold (∼50 mg daily opioid dose) for addiction screening.
Copyright © 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Long-term opioid therapy; chronic pain; opioid dosage; substance abuse; therapeutic opioid addiction

Mesh:

Substances:

Year:  2014        PMID: 25463699     DOI: 10.1016/j.jpain.2014.10.011

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  4 in total

Review 1.  Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.

Authors:  Charl Els; Tanya D Jackson; Diane Kunyk; Vernon G Lappi; Barend Sonnenberg; Reidar Hagtvedt; Sangita Sharma; Fariba Kolahdooz; Sebastian Straube
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

Review 2.  Preventing Opioid Overdose in the Clinic and Hospital: Analgesia and Opioid Antagonists.

Authors:  Stephanie Lee Peglow; Ingrid A Binswanger
Journal:  Med Clin North Am       Date:  2018-07       Impact factor: 5.456

3.  Magnesium Salt, a Simple Strategy to Improve Methadone Analgesia in Chronic Pain: An Isobolographic Preclinical Study in Neuropathic Mice.

Authors:  Valeria González; Teresa Pelissier; Victoria Cazanga; Alejandro Hernández; Luis Constandil
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

4.  Prevalence of and Factors Associated With Long-term Concurrent Use of Stimulants and Opioids Among Adults With Attention-Deficit/Hyperactivity Disorder.

Authors:  Yu-Jung Jenny Wei; Yanmin Zhu; Wei Liu; Regina Bussing; Almut G Winterstein
Journal:  JAMA Netw Open       Date:  2018-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.